TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30343318

Group type: COMPARATOR
Intervention: 2-L/kg/min high-flow nasal cannula (HFNC)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 3-L/kg/min high-flow nasal cannula (HFNC)
Number of subjects: 286
Study: 26933813

Group type: EXPERIMENTAL
Intervention: 100 million allo-hMSCs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 200 million allo-hMSCs
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 25490946

Group type: EXPERIMENTAL
Intervention: School-based health promotion intervention
Number of subjects: 1440
Study: 22951670

Group type: EXPERIMENTAL
Intervention: Test of Memory Malingering (TOMM) with CNS measures
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard TOMM scores
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: TOMM CNS scores
Number of subjects: 311
Study: 20412883

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 52
Study: 18663167

Group type: EXPERIMENTAL
Intervention: 1000 kcal/wk physical activity
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 2000 kcal/wk physical activity
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vigorous intensity physical activity
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Performing more physical activity (1835 kcal/wk or 275 min/wk)
Number of subjects: 201
Study: 21966753

Group type: COMPARATOR
Intervention: Progesterone (100 mg/day IM)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg of estradiol valerianate) plus progesterone (100 mg/day IM)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Estradiol levels on day 7 post-transfer
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Progesterone levels on day 7 post-transfer
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Estradiol levels predictive of pregnancy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Progesterone levels predictive of pregnancy
Number of subjects: 69
Study: 12161047

Group type: EXPERIMENTAL
Intervention: Menorest 50 microg/24 h (estradiol 4.3 mg) and Gestapuran 2.5 mg (medroxyprogesteron) daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 10583115

Group type: EXPERIMENTAL
Intervention: 10 p.p.m. nickel concentration in water for 10 min daily for the first week, followed by 100 p.p.m. nickel concentration for the second week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water immersion (control group)
Number of subjects: 0
Study: 8947405

Group type: EXPERIMENTAL
Intervention: Optical catheter fiberoptic system
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard rod-lens arthroscope
Number of subjects: 44
Study: 1341246

Group type: EXPERIMENTAL
Intervention: Intensified follow-up (Group II)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional follow-up (Group I)
Number of subjects: 106
Study: 6393417

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of Prednisolone and Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 21
Study: 31536101

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily (n=3023)
Number of subjects: 6042

Group type: COMPARATOR
Intervention: Glimepiride 1 to 4 mg once daily (n=3010)
Number of subjects: 6042
Study: 30421996

Group type: EXPERIMENTAL
Intervention: Playing as an immigration inspector
Number of subjects: 0

Group type: COMPARATOR
Intervention: Playing a similar game as a newspaper editor
Number of subjects: 0
Study: 26660265

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention to implement brief smoking cessation counseling based on the 5As
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 20
Study: 24524204

Group type: EXPERIMENTAL
Intervention: Daily Sedation Interruption (DSI) in combination with protocolized sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protocolized continuous sedation
Number of subjects: 0
Study: 22871933

Group type: EXPERIMENTAL
Intervention: Zilpaterol HCl (8.33 mg/kg DM)
Number of subjects: 3382

Group type: EXPERIMENTAL
Intervention: Zilpaterol HCl (8.33 mg/kg DM) with 148 DOF
Number of subjects: 3382
Study: 20298254

Group type: EXPERIMENTAL
Intervention: 1,064‐nm Q‐switched neodymium-doped yttrium aluminum garnet (QS‐Nd:YAG) laser treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Topical treatment (2% hydroquinone)
Number of subjects: 22
Study: 17522081

Group type: COMPARATOR
Intervention: Group A (no observation time post-ablation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (30 min observation time post-ablation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (60 min observation time post-ablation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (30 min observation time)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (60 min observation time)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (30 min observation time)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (60 min observation time)
Number of subjects: 90
Study: 16294613

Group type: EXPERIMENTAL
Intervention: Self-monitoring techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attentional control group
Number of subjects: 0
Study: 11932276

Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g daily for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wheat-based comparative control regimen (40 g daily for 3 months)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flaxseed and Wheat-based comparative control regimen
Number of subjects: 100
Study: 9795409

Group type: EXPERIMENTAL
Intervention: BMT (bismuth subsalicylate 600 mg t. i. d. for 28 days, metronidazole 400 mg t. i. d. and tetracycline 500 mg q. i. d. for ten days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OA (omeprazole 40 mg o. d. and amoxicillin 750 mg q. i. d. for 14 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OC (omeprazole 40 mg o. d. and clarithromycin 500 mg b. i. d. for 14 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OT (omeprazole 40 mg o. d. and tetracycline 500 mg q. i. d. for 14 days)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OMC (omeprazole 40 mg o. d., metronidazole 400 mg t. i. d. and clarithromycin 250 mg b. i. d. for seven days)
Number of subjects: 220
Study: 8578768

Group type: EXPERIMENTAL
Intervention: DV‐7751a 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DV‐7751a 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DV‐7751a 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DV‐7751a 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DV‐7751a
Number of subjects: 0
Study: 2121802

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 421671

Group type: EXPERIMENTAL
Intervention: 10 mg xipamide daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 mg xipamide daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Higher dosages of xipamide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Erythrocyte deformability
Number of subjects: 16
Study: 31635815

Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg and 50mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimuscarinics (solifenacin 2.5, 5, and 10mg; tolterodine 4mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30883864

Group type: COMPARATOR
Intervention: LSD (100 μg)
Number of subjects: 27
Study: 27693447

Group type: EXPERIMENTAL
Intervention: Retropubic urethral sling placement
Number of subjects: 203

Group type: COMPARATOR
Intervention: No sling placement
Number of subjects: 203
Study: 26072330

Group type: EXPERIMENTAL
Intervention: Pegylated Interferon α (IFNα)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study: 24079847

Group type: EXPERIMENTAL
Intervention: Preparation intervention involving practice and feedback with cross-examination questions
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 164
Study: 21400127

Group type: EXPERIMENTAL
Intervention: Vessel sealing system uvulopalatoplasty (VSSU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Uvulopalatal flap (UPF)
Number of subjects: 31
Study: 19781211

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (high dose)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg (low dose)
Number of subjects: 150
Study: 16504645

Group type: EXPERIMENTAL
Intervention: Multiple risk factor intervention (MRFI) program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MRFI program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MRFI program and Conventional care
Number of subjects: 200
Study: 15246125

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study: 11059437

Group type: EXPERIMENTAL
Intervention: Usual care plus bi‐weekly automated assessment and self‐care education calls with telephone follow‐up by a nurse educator
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 9082038

Group type: EXPERIMENTAL
Intervention: Trans fatty acids (elaidic acid at 5.5% energy)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 16:0-rich fats
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: cis 18:1
Number of subjects: 27

Group type: COMPARATOR
Intervention: 16:0 and cis 18:1
Number of subjects: 27
Study: 8358980

Group type: EXPERIMENTAL
Intervention: Daily dosing of methotrexate (2.5mg oral daily doses, totaling 15 mg weekly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Weekly dosing of methotrexate (15 mg)
Number of subjects: 20
Study: 3526734

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg/day (6 X 20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 14
Study: 29863691

Group type: EXPERIMENTAL
Intervention: Cellex (0.1 mg daily for 10 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 52
Study: 27167103

Group type: EXPERIMENTAL
Intervention: ivabradine and beta-blockers
Number of subjects: 71

Group type: COMPARATOR
Intervention: beta-blockers alone
Number of subjects: 71
Study: 24309322

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil and leucovorin
Number of subjects: 143

Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 143
Study: 23106925

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 81
Study: 20863926

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol + Prostatic Plexus Block
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Propofol + Fentanyl
Number of subjects: 45
Study: 18037940

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT) and stem cell support
Number of subjects: 308

Group type: COMPARATOR
Intervention: No further treatment (observation)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with CHUT
Number of subjects: 308
Study: 15728054

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 64
Study: 12623421

Group type: EXPERIMENTAL
Intervention: Radiotherapy (involved field doses range from 40 to 48 Gy, median 44.5 Gy)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Combined therapy (radiotherapy followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone, by six cycles)
Number of subjects: 130
Study: 10390385

Group type: EXPERIMENTAL
Intervention: Tapering of inhaled corticosteroids (fluticasone propionate) at weekly intervals
Number of subjects: 28
Study: 8875517

Group type: EXPERIMENTAL
Intervention: Omegavenous 10% (fish oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liposyn III 10% (control)
Number of subjects: 0
Study: 1994595

Group type: EXPERIMENTAL
Intervention: Partial fundoplication (180‐200 degrees, Toupet)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Total fundoplication (360 degrees, Rossetti)
Number of subjects: 71
Study: 6339985

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31368057

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 27555294

Group type: EXPERIMENTAL
Intervention: Asparaginase treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Concomitant dexamethasone therapy
Number of subjects: 31
Study: 27703033

Group type: EXPERIMENTAL
Intervention: Video-Only (VO) training
Number of subjects: 1464

Group type: COMPARATOR
Intervention: Video Self-Instruction kit (VSI) training
Number of subjects: 1464
Study: 24735134

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 495
Study: 22780999

Group type: EXPERIMENTAL
Intervention: 1.5 g/day ginseng
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 g/day ginseng
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4.5 g/day ginseng
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 19534023

Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/d for 2 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17024220

Group type: EXPERIMENTAL
Intervention: Postoperative steroid drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single sub‐tenon injection of triamcinolone
Number of subjects: 40
Study: 15042637

Group type: EXPERIMENTAL
Intervention: Caregiver skill‐building (CSB) treatment intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information and support only (ISO) control intervention
Number of subjects: 0
Study: 11710414

Group type: EXPERIMENTAL
Intervention: 3 10-minute bouts of walking (N = 5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 30-minute bout of continuous walking (N = 6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-exercising group (N = 7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both exercise groups (3 10-minute bouts and 1 30-minute bout)
Number of subjects: 30
Study: 9643274

Group type: EXPERIMENTAL
Intervention: moexipril 15 mg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 97
Study: 7836708

Group type: EXPERIMENTAL
Intervention: Hormonal control and euglycaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia
Number of subjects: 6
Study: 3414729

Group type: EXPERIMENTAL
Intervention: 150 mg phenylpropanolamine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 75 mg phenylpropanolamine plus 400 mg caffeine
Number of subjects: 6

Group type: COMPARATOR
Intervention: 75 mg phenylpropanolamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31982647

Group type: EXPERIMENTAL
Intervention: Behavioral activation intervention administered in a 16-week freshman orientation course
Number of subjects: 540

Group type: COMPARATOR
Intervention: Standard orientation course
Number of subjects: 540
Study: 30489436

Group type: EXPERIMENTAL
Intervention: Learning to Live with Cancer (LTLWC) intervention program (BCIG, n = 30)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (BCCG, n = 22)
Number of subjects: 52
Study: 28606731

Group type: EXPERIMENTAL
Intervention: Higher urine albumin-creatinine ratio (ACR)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Lower estimated glomerular filtration rate (eGFR)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Higher urine ACR
Number of subjects: 2800
Study: 25514515

Group type: EXPERIMENTAL
Intervention: iTBS (intermittent theta burst stimulation) applied daily over dPMCright during a four-day hand training program using mirror training (MT) for 20 minutes daily.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control group CG) during the same four-day hand training program using mirror training (MT) for 20 minutes daily.
Number of subjects: 0
Study: 23948646

Group type: EXPERIMENTAL
Intervention: Kiosk with attached devices for healthy eating/weight monitoring
Number of subjects: 51

Group type: COMPARATOR
Intervention: General health/BP monitoring (attention-control)
Number of subjects: 51
Study: 21564047

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Number of subjects: 33

Group type: COMPARATOR
Intervention: 80 mg methylprednisolone acetate with 20 ml levobupivacaine 0.125%
Number of subjects: 33
Study: 17881183

Group type: COMPARATOR
Intervention: Tamoxifen (Tam) alone
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Cyclic Tamoxifen (8 weeks) and Megestrol acetate (MA) (8 weeks) for 2 years
Number of subjects: 489
Study: 16501401

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (n = 160)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Usual care (n = 164)
Number of subjects: 324
Study: 15164911

Group type: EXPERIMENTAL
Intervention: Home polysomnography
Number of subjects: 64

Group type: COMPARATOR
Intervention: Laboratory polysomnography
Number of subjects: 64
Study: 12213869

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9810030

Group type: EXPERIMENTAL
Intervention: Boswellia serrata gum resin 300 mg thrice daily for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactose 300 mg thrice daily for 6 weeks (Control)
Number of subjects: 40
Study: 7704170

Group type: EXPERIMENTAL
Intervention: Asthma outreach program
Number of subjects: 53
Study: 2667311

Group type: EXPERIMENTAL
Intervention: urapidil (60 mg twice daily)
Number of subjects: 295

Group type: COMPARATOR
Intervention: captopril (25 mg twice daily)
Number of subjects: 295
Study: 4694405

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anaesthetic alone
Number of subjects: 0
Study: 31454356

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNSs) provided monthly during screenings.
Number of subjects: 2330

Group type: EXPERIMENTAL
Intervention: Behavior change communication (BCC) on nutrition, health, and hygiene practices.
Number of subjects: 2330
Study: 27977231

Group type: EXPERIMENTAL
Intervention: African American Dementia Caregiver Problem Inventory (DCPI‐A)
Number of subjects: 0
Study: 25936784

Group type: EXPERIMENTAL
Intervention: Group Ca (needle aperture directed caudally)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Group Ce (needle aperture oriented in a cephalad direction)
Number of subjects: 82
Study: 24152981

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 21600552

Group type: EXPERIMENTAL
Intervention: Triclosan-coated polyglactin 910 sutures
Number of subjects: 450

Group type: COMPARATOR
Intervention: Polyglactin 910 sutures (Control)
Number of subjects: 450
Study: 19390547

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX-4
Number of subjects: 0
Study: 16393432

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 22
Study: 15246460

Group type: EXPERIMENTAL
Intervention: 2-deoxyglucose (2-DG) 40 mg/kg, i.v.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 28
Study: 11734428

Group type: EXPERIMENTAL
Intervention: 3% saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 20
Study: 9231871

Group type: EXPERIMENTAL
Intervention: 30-minute training session on facial movements
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 75
Study: 7695928

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 101

Group type: COMPARATOR
Intervention: Combined cardioplegia
Number of subjects: 101
Study: 3024828

Group type: EXPERIMENTAL
Intervention: Regimen B (cyclophosphamide, doxorubicin, vincristine, and etoposide)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Regimen A (cyclophosphamide, doxorubicin, and vincristine)
Number of subjects: 116
Study: 31157522

Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with radiofrequency (temperature maintained between 40°C and 42°C)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo group (radiofrequency power of 0 W)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with radiofrequency
Number of subjects: 28
Study: 30482135

Group type: EXPERIMENTAL
Intervention: Warm fluid bolus (500 mL of Ringer's acetate at 38°C)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cold fluid bolus (500 mL of Ringer's acetate at 22°C)
Number of subjects: 21
Study: 28225050

Group type: EXPERIMENTAL
Intervention: Vitamin B12 supplementation
Number of subjects: 91
Study: 25166221

Group type: EXPERIMENTAL
Intervention: BF Spiromax 160+9 μg b.i.d.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler 200+12 μg b.i.d.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 23040144

Group type: EXPERIMENTAL
Intervention: CapOpus plus TAU
Number of subjects: 103

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 103